Comparing the effects of vitamin E tocotrienol-rich fraction supplementation and α-tocopherol supplementation on gene expression in healthy older adults by Ghani, Siti Madiani Abdul et al.
1ORIGINAL ARTICLE
 ■ INTRODUCTION
Vitamin E is composed of eight naturally occurring isoforms, 
namely, four tocopherols (α-, β-, δ-, and γ) and four tocotrienols 
(α-, β-, δ-, and γ), which differ by the number and position of the 
methyl groups on the chromanol ring and the level of saturation in 
their side chains (1). The tocopherols have a saturated phytyl tail, 
while the tocotrienols have an unsaturated isoprenoid tail (2). In 
addition to its antioxidant properties, vitamin E also exerts non-
antioxidant functions, such as modulating DNA repair systems, 
gene expression and signal transduction (3).
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OBJECTIVES: This study aims to compare the differential gene expression resulting from tocotrienol-rich fraction 
and α-tocopherol supplementation in healthy older adults. 
METHODS: A total of 71 eligible subjects aged 50 to 55 years from Gombak and Kuala Lumpur, Malaysia, were 
divided into three groups and supplemented with placebo (n=23), α-tocopherol (n=24) or tocotrienol-rich fraction 
(n=24). Blood samples were collected at baseline and at 3 and 6 months of supplementation for microarray analysis. 
RESULTS: The number of genes altered by α-tocopherol was higher after 6 months (1,410) than after 3 months (273) of 
supplementation. α-Tocopherol altered the expression of more genes in males (952) than in females (731). Similarly, 
tocotrienol-rich fraction modulated the expression of more genes after 6 months (1,084) than after 3 months (596) 
and affected more genes in males (899) than in females (781). α-Tocopherol supplementation modulated pathways 
involving the response to stress and stimuli, the immune response, the response to hypoxia and bacteria, the 
metabolism of toxins and xenobiotics, mitosis, and synaptic transmission as well as activated the mitogen-activated 
protein kinase and complement pathways after 6 months. However, tocotrienol-rich fraction supplementation 
affected pathways such as the signal transduction, apoptosis, nuclear factor kappa B kinase, cascade extracellular 
signal-regulated kinase-1 and extracellular signal-regulated kinase-2, immune response, response to drug, cell 
adhesion, multicellular organismal development and G protein signaling pathways. 
CONCLUSION: Supplementation with either α-tocopherol or tocotrienol-rich fraction affected the immune and drug 
response and the cell adhesion and signal transduction pathways but modulated other pathways differently after 6 
months of supplementation, with sex-specific responses.
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Most commercially available vitamin E supplements contain 
only α-tocopherol (α-TF). This isoform is commonly used because 
of its high bioavailability; compared to other isoforms, it is easily 
recognized by the hepatic α-TF transfer protein (TTP), and it is 
enriched in human plasma and tissues (4). However, α-TF alone 
may not be the best formulation for vitamin E supplementation, 
because the intake of vitamin E should reflect its natural composition, 
which consists of all isomers (5). Emerging evidence has shown 
that tocotrienol has higher antioxidant activity (4) and more potent 
antihypercholesterolemic (6), anti-inflammatory (7), antithrombotic 
(8), anticancer (9,10,11), hepatoprotective (12) and neuroprotective 
(13) properties than tocopherol.
A previous study by Chin et al. (14) reported that vitamin 
E responses were age-dependent; tocotrienol-rich fraction 
(TRF) supplementation resulted in a greater reduction in total 
DNA damage in older adults (>50 y) than in younger adults 
(35-49 y). In addition, improved serum lipid profiles and levels of 
vitamins E and C, as well as decreased levels of protein and lipid 
damage, were observed in older adults supplemented with TRF 
(5). Furthermore, Eng et al. (15) found that changes in protein 
expression with TRF supplementation were more profound 
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in older individuals (49-51 y) than in younger individuals (34-
36 y). According to Marino et al. (16), nutrition could influence 
the health of males and females differently due to multifactorial 
inputs, including gene repertoires, sex steroid hormones, 
ontogenetic developments, environmental factors and differences 
in the bioavailability, metabolism, distribution, and elimination 
of nutrients. In addition to the uncertainty surrounding the sex-
specific responses to supplementation, it is still unclear whether 
the previously observed effects were entirely due to tocotrienol, 
because TRF contains traces of tocopherol. Therefore, the 
aim of this study was to compare the effects of α-TF with TRF 
supplementation in male and female subjects aged 50-55 years.
 ■ METHODS
Study Design
This study is a randomized, single-blinded, placebo-controlled 
trial approved by the Research and Ethics Committees of the 
Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM). 
Volunteers who gave informed consent were screened to ensure 
that they met the study’s inclusion (age 50-55 years, healthy, 
nonsmoker, no significant clinical diseases, and no current use of 
medications, alcohol or supplements) and exclusion criteria. A full 
physical examination, previous history of medical illnesses and 
blood hematology profile were also obtained from the volunteers 
to confirm suitability. Of the 523 screened volunteers, 71 fulfilled 
all inclusion and exclusion criteria. The volunteers (26 males and 
45 females) recruited from Gombak and Kuala Lumpur in Malaysia 
were distributed equally into three groups receiving either placebo 
(olive oil, n=23), α-TF (400 IU/day, n=24) or TRF (150 mg/day, 
n=24) capsules daily after dinner to ensure proper absorption. 
The treatment was double blinded throughout the study period 
until all data were collected, after which the randomization code 
was exposed. The subjects’ food intake frequency was assessed 
using a modified questionnaire by Chee et al. (17) before blood 
was sampled at the UKM Medical Centre. The subjects were 
encouraged to maintain their usual diet and lifestyle throughout the 
study period. Compliance was checked by counting the remaining 
capsules at each visit. Blood sampling was performed at baseline 
(month 0) and at 3 and 6 months of supplementation. Peripheral 
blood mononuclear cells (PBMCs) were isolated from whole blood 
for the evaluation of gene expression using a microarray. Of the 
recruited subjects, five from each group and each sex were used for 
the microarray analysis.
Vitamin E Capsules for Supplementation
All commercial capsules were prepared and supplied by Sime 
Darby Bioganic Sdn. Bhd. (previously known as Golden Hope 
Bioganic), Kuala Langat, Selangor, Malaysia. The TRF (Gold 
TriE® Tocotrienol) soft gelatin capsules consisted of approximately 
74% tocotrienol and 26% tocopherol extracted from palm oil. The 
α-tocopherol capsules contained 100% α-tocopherol, while the 
placebo capsules contained only olive oil.
Isolation of PBMCs
Briefly, a total of 35 ml whole blood was added to Lymphoprep 
solution (Biodiagnostic, US) and centrifuged at 1800 rpm for 
30 min at room temperature (25°C). The tube was removed 
carefully from the centrifuge (Axis-Shield PoC, Norway), where 
the resulting four layers were observed: a clear supernatant top 
layer, an opaque fluid upper middle layer containing the PBMCs, 
a lower middle layer containing Lymphoprep, and a bottom layer 
consisting of erythrocytes and granulocytes. The layer containing 
the PBMCs was transferred into a new tube, washed three times 
with phosphate-buffered saline (PBS) and centrifuged at 1,500 rpm 
for 10 min at room temperature. The pellet was resuspended in 3 ml 
of TRI-Reagent (Invitrogen Life Technologies, Carlsbad, CA) and 
stored at -80°C until use.
RNA Extraction from PBMCs and Quality Assessment
Total RNA was extracted from PBMCs and purified using an 
RNeasy Mini Kit (Qiagen, Valencia, CA). Extraction was conducted 
according to the kit manual. The RNA purity and concentration 
were determined by measuring the absorbance at 260 nm (A260) 
and 280 nm (A280) using a NanoDrop ND-1000 (Thermo Fisher 
Scientific, USA), while the RNA integrity was assessed by an RNA 
6000 Nano LabChip Kit using an Agilent 2100 bioanalyzer (Agilent 
Technologies, Palo Alto, CA).
Gene Expression Profiling (Microarray) 
The microarray target sample processing, target hybridization, 
washing, staining, and scanning steps were performed according 
to the manufacturer’s protocol (Illumina Inc., San Diego, CA). 
Briefly, samples of 50 ng of total RNA were amplified and 
transcribed in vitro into biotinylated cRNA using an Epicentre 
TargetAmpTM-Nano Labeling Kit (Ambion, Inc., Austin, TX). 
The samples were then washed using an RNeasy MinElute Cleanup 
Kit (Qiagen, Valencia, CA). The purified cRNA was loaded into 
an Illumina HumanHT-12 BeadChip and hybridized overnight 
(17 h) in a 58°C hybridization oven (Illumina Hybridization Oven). 
Unhybridized and nonspecifically bound cRNAs were removed and 
washed using the buffer provided in the BeadChip Hybridization 
Kit. The specifically bound, biotinylated cRNAs were visualized 
by Cy3-streptavidin, and the fluorescent signals were scanned using 
Illumina iScan Technology. Finally, the raw data were extracted 
from the scanned images and analyzed with GenomeStudio, Partek 
and Pathway Studio 11.2 software.
Quantitative Real-time Reverse Transcription PCR 
(RT-qPCR)
RT-qPCR was performed to quantitate and verify the level 
of mRNA expression found in the microarray experiment. The 
RNA samples used for microarray analysis were subjected to RT-
qPCR using a One-Step RT-qPCR Kit with SYBR Green (Bio-
Rad, Canada) according to the manufacturer’s protocol. The 
fluorescence signals were measured using an iCycler iQ5 Real-
Time PCR Detection System (Bio-Rad Laboratories, USA). The 
primers for the selected transcripts were designed using National 
Center for Biotechnology Information (NCBI) (http://www.ncbi.
nlm.nih.gov) resources. To maximize PCR efficiency, amplicons 
were designed to be fewer than 250 base pairs in length with a 
common melting temperature (56-61°C) for all primers. The 
efficiency and specificity of each primer set were confirmed using 
a standard curve (Ct value versus the serial dilution of total RNA) 
and agarose gel electrophoresis. The primer sequences (forward/
reverse) used for RT-qPCR are shown in Table 1. Briefly, the 
reaction was performed by mixing the samples with 1 µl of total 
RNA (100 ng), 2 µl of the primers (forward & reverse) and 17 µl 
of master mix (10 µl of 1×QuantiTect SYBR® Green solution, 
0.2 µl QuantiTect RT Mix, and 6.8 µl RNase-free water; all 
provided in the kit) and incubated in the iCycler instrument with 
the following reaction profile: cDNA synthesis for 10 min at 
50°C; predenaturation for 2 min at 95°C; and PCR amplification 
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for 38 cycles of 30 sec at 94°C and extension for 30 sec at 61°C. 
Each sample was amplified in duplicate, and the results were 
normalized to those of GAPDH as a reference gene. The relative 
expression values of the selected genes were calculated using the 
following equation:
Relative expression value (REV) = 2 Ct value of GAPDH - Ct value of selected gene
Ct =  threshold cycle
Fold change (FC) = REVtreatment/REVcontrol
Statistical Analysis
The comet assay and RT-qPCR data were analyzed using 
Statistical Package for Social Sciences 16.0 (SPSS, Inc., Chicago, 
IL, USA). ANOVA was used to compare the differences between 
groups, with p<0.05 as the significance level. The data are reported 
as the means±SEMs. Genes that did not meet the criteria for 
differential expression in the microarray analysis were removed by 
computing a 3-way ANOVA with a significance level of p<0.05. 
Genes that changed in expression by less than 1.5-fold were also 
removed from subsequent analysis. Gene Set Enrichment Analysis 
(GSEA) was performed using a nonparametric Kolmogorov-
Smirnov statistical test to calculate the p value of the biological 
processes/pathways across the whole database most affected 
by supplementation based on the gene regulation data in our 
experimental dataset. Fisher’s exact test was then conducted to 
determine the specific biological processes/pathways affected 
by supplementation according to the list of significant genes. 
Functional attribution was made by referring to online databases, 
and biological interpretation was obtained from the literature.
 ■ RESULTS
Subject Demographics
The 26 male and 45 female subjects recruited from the Gombak 
and Kuala Lumpur area were not significantly different in body 
mass index (BMI), blood pressure, glucose or total cholesterol 
throughout the study period (Table 2).
Modulatory effects of Vitamin E on Gene Expression 
and Pathways
A total of 71 individual BeadChips were analyzed using Partek 
software. Further analysis with a 3-way ANOVA using Partek and 
Pathway Studio 11.2 software revealed that at p<0.05, the total 
number of up- and downregulated genes modulated by 3 months 
of α-TF and TRF supplementation was similar to the number 
modified by 6 months of supplementation. Further analysis by 
sex revealed that more genes were modulated in the male subjects 
after 3 months than after 6 months of supplementation with either 
vitamin supplement. However, after filtering the gene list at a cutoff 
fold change of 1.5-fold, the total number of genes modulated by 
the vitamins was slightly lower after 3 months than after 6 months 
of supplementation in both male and female subjects (Table 3). 
Considering both sexes and both supplementation time points, α-TF 
supplementation modulated a total of 1,683 genes; TRF, 1,680.
Hierarchical clustering showed that all samples from the same 
supplementation group (according to the supplement type, time 
point and sex) grouped well based on the similarity of the gene 
expression profiles (Figure 1). GSEA was conducted on a list 
of differentially expressed genes (p<0.05) with a fold change of 
>1.0 (obtained from Partek analysis) to identify the functional 
categories of the genes. Fisher’s exact test was performed to 
compute the p values in order to determine the overlap between the 
entities (gene set) and pathways. The gene ontology (pathway) was 
ranked based on the highest p value (Supplementary Table S1-S8).
Three months of supplementation with α-TF upregulated the 
immune system, responses to cyclic adenosine monophosphate 
(cAMP) and oxidative stress pathways as well as the negative 
regulation of smooth muscle cell proliferation pathway in the 
male subjects (Figure 2; Supplementary Table S1). Six months of 
supplementation with α-TF upregulated the mitosis, glucose import 
and cellular response to hypoxia pathways but downregulated 
the responses to bacterium, complement activation and mitogen-
activated protein kinase (MAPK) activity pathways in the male 
subjects (Figure 2; Supplementary Table S2). In the female 
subjects, α-TF supplementation upregulated the toxin metabolic 
Table 1 - Primer sequences for real-time quantitative RT-PCR.
Accession numbera Genes
Sequence (5'→3')
Sense and antisense primers
Product size (base pairs, bp)
NM_002046 GAPDH
F: tcc ctg agc tga acg gga ag 
R: gga gga gtg ggt gtc gct gt
217
NM_000546 TP53
F: tgt gac ttg cac gta ctc cc 
R: acc atc gct atc tga gca gc
199
NM_006167 NKX3-1
F: ccc aca ctc agg tga tcg ag 
R: gtc tcc gtg agc ttg agg tt
103
NM_003879 CFLAR
F: ttg tgc cgg gat gtt gct at
R: aga gca gtt cag cca agt cc
109
NM_198589 BSG
F: ttc atc tac gag aag cgc cg
R: cag gaa gag ttc ctc tgg cg
131
NM_003862 FGF18
F: aag tcc gga tca agg gca ag
R: tca ggg ccg tgt agt tgt tc
138
NM_002423 MMP7
F: gga gct cat ggg gac tcc ta
R: tcc agc gtt cat cct cat cg
115
NM_001825 CKMT2
F: gtt cga cga gca tta cgt gc
R: cag tga tgg cca cgt tct ct
122
NM_021116 ADCY1
F: ggt ttg gca gct cct ttt gg
R: gga acg cct tcc tct gtg aa
245
aeSource of accession number is the NCBI, http://www.ncbi.nlm.nih.gov/gene/.
GAPDH: glyceraldehyde-3-phosphate dehydrogenase; TP53: tumor protein p53; NKX3-1: androgen-regulated homeobox gene; CFLAR: apoptosis regulator; 
BSG: basigin-encoding plasma membrane protein in spermatogenesis; FGF18: fibroblast growth factor 18; MMP7: matrix metalloproteinase-7; CKMT2: 
mitochondrial creatine kinase-2; ADCY1: adenylyl cyclase type 1.
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processes, responses to stimuli, xenobiotic metabolic processes 
and synaptic transmission pathways but downregulated the 
cellular responses to stress pathway after 3 months (Figure 2; 
Supplementary Table S3). Supplementation with α-TF for 6 months 
upregulated the insulin secretion and transmembrane ion transport 
pathways but downregulated the responses to lipopolysaccharide 
(LPS), chemotaxis, and interleukin-1 (IL-1) pathways in the female 
subjects (Figure 2; Supplementary Table S4).
For TRF, 3 months of supplementation in the male subjects 
upregulated the cell division, regulation of cell transcription 
and G protein-coupled receptor signaling pathways (Figure 2; 
Supplementary Table S5). However, 6 months of supplementation 
with TRF upregulated only the growth pathway but downregulated 
the integrin-mediated signaling, phosphatidylinositol-mediated 
signaling, cell-cell signaling and extracellular signal-regulated 
kinase 1/2 (ERK1/2) cascade pathways in the male subjects 
(Figure 2; Supplementary Table S6). Among the female subjects, 
3 months of supplementation with TRF upregulated the G protein-
coupled receptor signaling, protein kinase activity, and growth 
and responses to glucocorticoid pathways but downregulated the 
cell surface receptor signaling pathway (Figure 2; Supplementary 
Table S7). Six months of TRF supplementation upregulated only 
the growth pathway in the female subjects but downregulated the 
ERK1/2 cascade, G protein-coupled receptor signaling, cell surface 
receptor signaling, apoptosis and I-kappa B kinase-nuclear factor-
kappa B signaling pathways (Figure 2; Supplementary Table S8).
The biological processes that were modulated similarly by 
α-TF and TRF supplementation were the immune system, drug 
response, cell adhesion and signal transduction processes. These 
processes were downregulated in both males and females mainly 
after 6 months of supplementation.
Gene Validation
To validate the microarray results, the mRNA transcript 
levels of six downregulated genes and one upregulated gene were 
quantified by real-time RT-qPCR using the PBMC samples from 
each subject. Genes were selected based on their function and their 
identification as a major and significantly differentially regulated 
gene in any biological process generated by GSEA and Fisher’s 
exact test. Overall, the fold changes in the differentially expressed 
genes in the RT-qPCR analysis were consistent and in agreement 
with the microarray analysis results (Figure 3).
 ■ DISCUSSION
In the elderly, the intake of essential macro- and micronutrients 
from the diet is usually inadequate. The deficiency of essential 
nutrients in aging is related to the global impairment of immune 
functions, metabolic harmony and antioxidant defense (18). With 
increasing age, the production of reactive oxygen species (ROS) 
is also increased due to an imbalance between antioxidant defense 
and ROS production. The resulting oxidative stress damages 
biomolecules such as DNA, protein and lipids, which eventually 
contributes to age-related diseases (19). Thus, supplementation 
with micronutrients with antioxidant properties, such as vitamin E, 
could prevent oxidative stress and molecular injury in aging.
Table 3 - Total number of up- and downregulated genes modulated in male and female subjects after 3 and 6 months of α-TF and TRF 
supplementation.
Group
α-TF vs Placebo TRF vs Placebo
Male Female Male Female
3 months 6 months 3 months 6 months 3 months 6 months 3 months 6 months
Differentially expressed genes with p<0.05:
Up 1,258 935 737 966 629 647 530 681
Down 951 1,042 719 1,152 717 551 488 592
Total 2,209 1,977 1,456 2,118 1,346 1,198 1,018 1,273
Differentially expressed genes with p<0.05 and fold change ≥1.5:
Up 44 338 61 270 150 247 107 277
Down 96 474 72 328 224 278 115 282
Total 140 812 133 598 374 525 222 559
Table 2 - Demographic data of the study groups.
Supplementation Groups
Placebo
(Control)
α-Tocopherol (α-TF)
Tocotrienol-Rich  
Fraction (TRF)
Age (years) 52.2 ± 2.1 52.5 ± 2.5 53.4 ± 1.5
Sex (male/female) 8/15 9/15 9/15
Body Mass Index (BMI) [kg/m2] 26.4 ± 0.8 26.2 ± 0.8 25.3 ± 0.7
Blood Pressure (BP) [mmHg]: 
- Systolic 123.5 ± 2.5 131.1 ± 3.3 130.6 ± 2.9
- Diastolic 78.3 ± 2.1 81.3 ± 1.5 80.0 ± 2.1
Pulse (beats per minute) 73 ± 2 72 ± 2 74 ± 2
Fasting Blood Sugar (FBS) 5.09 ± 0.1 4.94 ± 0.1 4.91 ± 0.1
Total Cholesterol (Ch) 5.2 ± 0.2 5.6 ± 0.1 5.6 ± 0.1
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The effects of α-TF and TRF on healthy older adults were 
compared in this study, and our results showed that each vitamin 
modulated the expression of different genes and regulated different 
pathways. Although the TRF supplements used in this study also 
contained α-tocopherol, the responses were different from the 
responses to α-TF supplementation alone. In the male subjects, 
α-TF supplementation for 3 months significantly stimulated the 
defense response pathway (p<0.007). Although this pathway 
was stimulated, the expression of most related genes (FC>1.5) 
decreased. The expression of the CD3ε, or CD3-epsilon, gene 
(Entrez ID: NM_000733) (http://www.ncbi.nlm.nih.gov/gene/) 
was found to decrease with the highest fold change (1.6-fold). 
The CD complex plays an important role in coupling antigen 
recognition to several intracellular signal transduction pathways, 
such as T cell receptor (TCR) signal transduction (20). According 
to Li et al. (21), increased CD3ε expression is related to the 
severity of aplastic anemia, which is an autoimmune disease. 
The results of this study suggest that α-TF induces a cellular 
defense response against pathogenic conditions by decreasing the 
expression of CD3ε, which plays a role in autoimmune diseases. 
In addition, α-TF exerts an antiproliferative effect by upregulating 
the response to cAMP (11) and downregulating smooth muscle 
cell proliferation (22). The role of this vitamin as an antioxidant is 
also established, as the oxidative stress pathway was upregulated 
(23). The most significant pathway modulated after 6 months of 
α-TF supplementation was the mitosis pathway (p<0.008), which 
plays a crucial role in the cell cycle (24). Upregulated mitosis 
shows that α-TF promotes cell cycle progression and cell division. 
The expression of the gene SNX9, or sorting nexin 9 (Entrez ID: 
NM_016224), was found to increase with the highest fold change 
(2.1-fold) in this pathway. According to Ma and Chircop (25), the 
SNX9 protein is essential for the progression and completion of 
mitosis, and the depletion of this protein induces multinucleation 
(an indication of cytokinesis failure) and the accumulation of 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
 
 
 
 
TF0M TF3M TF6M TF6F TF0F TF3F 
TRF6M TRF3M TRF0M TRF6F TRF3F TRF0F 
(a) (b) 
(c) (d) 
Figure 1 - Hierarchical clustering of α-TF and TRF supplementation. Similar gene expression profiles were joined to form a group. The 
expression profiles of the corresponding genes were considered to be significantly different at a fold change of ≥1.5 and p<0.05. Red 
indicates overexpressed genes, while green indicates inhibited genes. (a) α-TF supplementation in males after 3 and 6 months compared 
to 0 months. (b) α-TF supplementation in females after 3 and 6 months compared to 0 months. (c) TRF supplementation in males after 
3 and 6 months compared to 0 months. (d) TRF supplementation in females after 3 and 6 months compared to 0 months.
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cytokinetic cells. In addition, α-TF may have anti-inflammatory 
effects, as supplementation was found to downregulate the cell 
adhesion and cell response to bacterium pathways and inhibit 
proliferation by decreasing the activation of the MAPK activity 
pathway (26) in healthy male subjects.
In female subjects, the most significant pathway modulated by 
α-TF after 3 months of supplementation was the toxin metabolic 
process pathway (p<0.008). The upregulation of this pathway 
shows that α-TF may promote detoxification by eliminating 
various types of toxins, such as mutagens, carcinogens, drugs, 
excessive hormones and chemicals (27), from the body after as few 
as 3 months of supplementation. At this time point, α-TF was also 
found to upregulate xenobiotic metabolism, which is also related 
to the detoxification mechanism. Although both pathways were 
upregulated, the expression of most of the genes involved in these 
pathways was found to decrease. The expression of the CYP1A1, 
or cytochrome P450 family 1 subfamily A member 1, gene (Entrez 
ID: NM_000499) was found to decrease with the highest fold 
change (1.5-fold). This gene encodes the P450-1A1 (CYP1A1) 
enzyme, which has aryl hydrocarbon hydroxylase activity (28). 
This enzyme converts polycyclic aromatic hydrocarbons (PAHs) 
to aryl epoxide carcinogens (29) and participates in estrogen 
metabolism by catalyzing the 2-hydroxylation of estradiol, 
which results in free radical and DNA adduct production (30). 
The decreased expression of this gene may inhibit the production 
of ROS that lead to cancer development. After 6 months of 
supplementation, α-TF significantly downregulated the signal 
transduction pathway (p<0.007). Signal transduction (also known 
as cell signaling) is a process of (chemical or physical) signal 
transmission through a cell that results in a response that may 
alter cell metabolism or gene expression (31). In this pathway, 
the expression of the TP53, or tumor protein 53, gene (Entrez 
ID: NM_000546) was downregulated by 1.5-fold. This gene 
encodes a tumor suppressor protein that has a DNA binding 
site and transcriptional activation and oligomerization domains 
that respond to diverse cellular stresses to regulate targeted 
genes by inducing apoptosis, cell cycle arrest, DNA repair, 
senescence, or metabolic changes. Ishak et al. (32) reported 
that the increased expression of TP53 was detected in 50% of 
gallbladder carcinomas. According to Barabutis et al. (33), p53, 
which functions as a tumor suppressor, promotes apoptosis, cell 
cycle arrest and senescence under stress conditions. In this study, 
the decreased expression of the TP53 gene may be related to a 
decreased stress response with α-TF supplementation, leading 
to a downregulated signaling cascade as well as a decreased 
response to LPS, IL-1 and chemotaxis. α-TF may also exert anti-
inflammatory effects by downregulating the cell adhesion (34) and 
cellular responses to iIL-1 pathways in healthy female subjects.
The G protein-coupled receptor signaling pathway was 
upregulated after 3 months of TRF supplementation in male subjects 
(0.007). G protein-coupled receptors (GPCRs) are located at the 
cell surface to convert endogenous signals or stimuli into a series of 
cellular responses (35). Although this pathway was upregulated by 
supplementation, most of the significant genes (FC>1.5) involved 
in this pathway were found to be downregulated, especially the 
GPR110, or the adhesion G protein-coupled receptor F1, gene 
(Entrez ID: NM_025048), which was downregulated with the 
highest fold-change (2.4-fold). GPR110 is an orphan GPCR that 
has been identified as an oncogene overexpressed in some lung and 
prostate cancers and is used as a disease marker and therapeutic 
Figure 2 - Biological processes significantly modulated in both male and female subjects after 3 and 6 months of α-TF and TRF supplementation.
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target for both types of tumors (36). Short-term supplementation 
with TRF may also promote the cell cycle by upregulating the 
cell division pathway and delay aging by downregulating the 
aging pathway. The most significant pathway upregulated after 
6 months of TRF supplementation was the multicellular organismal 
development pathway (p=0.006). The CTNDD2, or delta 2 catenin, 
gene (Entrez ID: NM_001332) was upregulated with the highest 
fold change (1.9-fold). This gene encodes a δ-catenin and is 
involved in the regulation of dendrite function and neuronal 
migration in the mature cortex (37). Intragenic CTNND2 deletion 
is found in patients with isolated intellectual disability (38). Based 
on these results, TRF has been suggested to have a neuroprotective 
effect in male subjects by downregulating the ERK1/2 cascade 
(13). TRF also exerts anti-inflammatory effects by decreasing 
cell adhesion (39) and suppressing integrin-mediated signaling, 
phosphatidylinositol-mediated signaling and cell-cell signaling 
pathways in male subjects.
In the female subjects, the biological process most significantly 
modulated after 3 months of TRF supplementation was the activation 
of protein kinase pathway (p<0.008). Protein kinase activity is 
modified by other proteins via phosphorylation, which results in the 
alteration of protein function (40). Though this process was stimulated 
by TRF supplementation, the expression of all the significant genes 
(FC>1.5) involved was decreased. The expression of the epidermal 
growth factor (EGF) gene was found to decrease with the highest fold 
change (2.2-fold) after supplementation. Decreased EGF expression 
is beneficial for the prevention of breast cancer because EGF is a 
potent mitogen for normal and neoplastic mammary epithelial cells 
(12). Indeed, McIntyre et al. (41) reported that tocotrienols specifically 
inhibit EGF-dependent mitogenesis in preneoplastic and neoplastic 
mammary epithelial cells. Like α-TF supplementation, TRF 
supplementation for 6 months downregulated the signal transduction 
pathway significantly (p<0.006). Among the genes in this pathway, 
TRF downregulated the LTB4R2, or leukotriene B4 receptor 2, gene 
(Entrez ID: NM_001164692) with the highest fold change (2.4-fold). 
LTB4 is reported to be a potent proinflammatory lipid mediator that 
is overproduced in the pathogenesis of several inflammatory diseases 
(42), such as rheumatoid arthritis, bronchial asthma, ischemic renal 
failure, psoriasis and inflammatory bowel diseases (43). Studies 
have shown that LTB4 and its receptors critically regulate tumor 
progression by promoting cell proliferation, migration, survival 
and metastasis (44, 45). Kim et al. (46) reported that the expression 
of the LTB4R2 gene (also known as BLT2) was upregulated in 
MCF-7 (a human breast cancer cell line)/DOX (doxorubicin) cells, 
whereas cotreatment with a BLT2 inhibitor markedly reduced 
tumor growth in an in vivo MCF-7/DOX model. TRF also exerts 
antiapoptotic effects by downregulating the apoptotic process 
pathway (47); furthermore, it shows neuroprotective properties by 
decreasing the ERK1/2 cascades (15,16) and anti-inflammatory and 
anticancer properties by downregulating the I-kappa B kinase-NF-
kappa B signaling (48) and cell adhesion pathways (39) in healthy 
female subjects.
Overall, supplementation with either α-TF or TRF modulated 
the immune system, response to drug, cell adhesion and signal 
transduction pathways. de Magalhaes et al. (49) reported that age-
related gene changes most notably involve an overexpression of 
immune response genes. Theriault et al. (39) reported that the 
anti-inflammatory and cardioprotective effects of tocotrienols are 
mediated through the ability of tocotrienols to downregulate the 
expression of adhesion molecules. For example, α-TF has been 
reported to prevent inflammation and atherosclerosis by reducing 
monocyte cell adhesion activity (50). Zingg (3) reported that vitamin 
E specifically modulates signal transduction in order to scavenge 
free radicals by directly interacting with signal transduction enzymes 
or by reducing ROS- and reactive nitrogen species (RNS)-induced 
damage to enzymes. Furthermore, Khanna et al. (51) showed that 
the neuroprotective effect of α-tocotrienol did not result from its 
antioxidant activity but from the suppression of specific signal 
transduction mediators. In this study, the ability of both types of 
vitamin E to suppress the signal transduction pathway may have 
led to the downregulation of most biological processes, especially 
in female subjects after 6 months of supplementation. Although the 
distribution of males and females in each supplementation group 
was similar, the study was limited because the number of females 
was greater than the number of males. Thus, further research 
encompassing a larger sample size with an equal distribution of 
Figure 3 - Comparison of gene expression between the microarray and RT-qPCR results.
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males and females is necessary to confirm the sex-specific effects 
of α-TF and TRF supplementation observed in this study. 
Both α-TF and TRF supplementation had similar effects on the 
immune system, drug response, cell adhesion and signal transduction 
pathways. However, TRF supplementation showed a more 
pronounced effect than α-TF in modulating the expression of genes 
in signaling pathways. The antioxidative and anti-inflammatory 
properties of TRF observed in female subjects may be attributed to 
the downregulation of the apoptotic pathway, ERK1/2 cascades and 
NF-kB pathway after 6 months of supplementation.
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Supplementary Table 2 - List of biological processes significantly modulated in male subjects after 6 months of α-TF supplementation
BIOLOGICAL PROCESS/
PATHWAY
GENE SET ENRICHMENT 
ANALYSIS (GSEA)
FISHER’S EXACT TEST: ENRICHED PATHWAYS
Normalized 
enrichment score 
(NES)
p-value Overlapping genes in database Total entities p-value
Mitosis 1.32 (↑) 0.008
KLHL9(↓);NEK2(↓);TPX2(↓);KIF11(↓);KIF18B(↑);
SNX9(↑);CDC25A(↓);VCPIP(↓);CDKN1A(↑)
252 0.009
Positive regulation of 
glucose import
1.67 (↑) 0.009 IRS1(↑);IRS2(↑);GLP1R(↑) 35 0.03
Response to bacterium -1.53 (↓) 0.009 NLRP6(↓);IL6(↑) 37 0.04
-ve regulation of 
immune response†TRF3M, 
TRF3F & TRF6F
1.64 (↑) 0.01
EXO1(↓);INPP5D(↑);PDCD1(↓);CD180(↓);MR1(↑);
TNFSF18(↓)
14 0.002
Complement activation -1.51 (↓) 0.01 MBL2(↑);C8B(↑);CFLAR(↓) 28 0.02
Activation of MAPK 
activity
-1.51 (↓) 0.01 PTPRC(↓);AVPI1(↑);HBEGF(↑) 99 0.01
Cell adhesion†TF6F, TRF6M, TRF6F -1.22 (↓) 0.01
PCDH19(↓);PKN2(↓);DCBLD2(↓);COL15A1(↓); 
CDH15(↑);CLDN1(↑);COL8A1(↑); THBS4(↑);CUZD1(↓);RHOB(↑); 
CNTN2(↑); RGMB(↑);DH9(↓);CDH12(↑);SDK2(↓) 
593 0.001
Cellular response to 
hypoxia
1.28 (↑) 0.01 NKX3-1(↑);TP53(↓);ITPR2(↓);VEGFA(↑);SIRT1(↓) 99 0.06
†Similar effects to TRF 3 months male (TRF3M), TRF 3 months female (TRF3F), TRF 6 months female (TRF6F), α-TF 6 months female (TF6F), and TRF 6 months 
male (TRF6M)
Supplementary Table 1 - List of biological processes and genes significantly modulated in male subjects after 3 months of α-TF 
supplementation
BIOLOGICAL PROCESS/
PATHWAY
GENE SET ENRICHMENT 
ANALYSIS (GSEA)
FISHER’S EXACT TEST: ENRICHED PATHWAYS
Normalized 
enrichment score 
(NES)
p-value Overlapping genes in database Total entities p-value
Defense response 1.54 (↑) 0.007
MLF2(↓);CEBPE(↓);LSP1(↓);DARC(↓);CLEC1A(↓);
CD3E(↓);TNFRSF4(↑);ITGAM(↓);MYC(↑);ELAVL1(↑)
98 0.02
Response to cAMP 1.50 (↑) 0.008
CDK2(↑);PEBP1(↑);BIRC2(↓);CITED1(↓);BSG(↓);
PTK2B(↓);CD4(↓)
67 0.03
Response to oxidative 
stress (OS)
1.40 (↑) 0.009
PARK7(↑);PPID(↑);TP53(↓);JAK2(↓);PEBP1(↑);
PXDN(↓);SIRT1(↓);COQ7(↑);ALAD(↑);ERCC3(↑);
GPX4(↓)
138 0.002
-ve regulation of 
smooth muscle cell 
proliferation
1.65 (↑) 0.01 FGFR2(↓);CALCRL(↓);NOX1(↑);FGF2(↓) 62 0.03
+ve regulation of 
reactive oxygen species 
metabolic process
1.63 (↑) 0.01 ROMO1(↓);TP53(↓);PID1(↓);PTK2B(↓) 31 0.04
Immune system process 1.33 (↑) 0.01 CD4(↓);SEMA4A(↓);JAK2(↓);INPP5D(↑);ITK(↑);
CFP(↓);ORAI1(↓);IRF1(↑)
365 0.001
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Supplementary Table 3 - List of biological processes significantly modulated in female subjects after 3 months of α-TF supplementation 
BIOLOGICAL PROCESS/
PATHWAY
GENE SET ENRICHMENT ANALYSIS 
(GSEA)
FISHER’S EXACT TEST: ENRICHED PATHWAYS
Normalized 
enrichment score 
(NES)
p-value Overlapping genes in database Total entities p-value
Toxin metabolic process 1.61 (↑) 0.008 FMO2(↓);CYP1A1(↓) 9 0.02
Cellular response to stress -1.62 (↓) 0.009 PDCD6(↑);SRPX(↑) 13 0.02
Response to stimulus 1.33 (↑) 0.01
GUCA1A(↑);MYO3A(↑);RP1(↓);NRL(↓);LCN1(↓);
TULP1(↓);PTN(↓);KAT5(↑)
393 0.001
Xenobiotic metabolic 
process
1.31 (↑) 0.01
CYP19A1(↓);FMO2(↓);SULT4A1(↓);ADH1C(↓);
CYP1A1(↓);CYP2F1(↓);GSTP1(↓);CNGB3(↓)
159 0.007
Positive regulation of 
uterine smooth muscle 
contraction
1.56 (↑) 0.01 ADRA2B(↓);TACR1(↓);TACR2(↓);IFNB1(↓) 7 0.03
Synaptic transmission 1.20 (↑) 0.01 GABARAP(↓);KCNJ6(↑);GNGT1(↓);CACNG3(↑);
KCNC3(↑);GRIA1(↓); GRIN1(↓);MT3(↑)
442 0.001
Supplementary Table 4 - List of biological processes significantly modulated in female subjects after 6 months of α-TF supplementation 
BIOLOGICAL PROCESS/
PATHWAY
GENE SET ENRICHMENT 
ANALYSIS (GSEA)
FISHER’S EXACT TEST: ENRICHED PATHWAYS
Normalized 
enrichment score 
(NES)
p-value Overlapping genes in database Total entities p-value
Signal transduction†TRF6M, TRF6F -1.20 (↓) 0.007
GPR151(↑);AHRR(↑);GPR139(↓);ARR3(↑);IRS2(↑);OST-
F1(↓);HPGDS(↑);RASD1(↑);TAS2R7(↓);IL21(↑); 
PTCH1(↓);GPR39(↑);PDE6B(↓);HTR2B(↑);HBEG-
F(↑);IRS1(↑);GPR45(↑);OR4C13(↓); PKN2(↓);C-
GA(↑);ADRBK2(↓);CHRNA6(↓)
1036 0.001
Cell adhesion†TF6M, TRF6M, TRF6F -1.27 (↓) 0.008
HES1(↑);PKN2(↓);PCDHA4(↓);EPHB4(↑);HAPLN3(↑);
RHOB(↑);CX3CL1(↑);CDH9(↓);RADIL(↓);PCDHGB3(↓);
SDK2(↓);PPARGC1A(↓)
593 0.001
Response to drug †TRF3M, TRF6M, TRF6F -1.29 (↓) 0.008
HTR2B(↑);TP53(↓);CYP11A1(↓);JUN(↑); 
PTCH1(↓);FOS(↑);
CDKN1A(↑);FECH(↑);SOCS3(↑);1L6(↑)
450 0.01
Response to lipopolysaccharide -1.32 (↓) 0.008 CASP8(↓);CFLAR(↓) 208 0.009
Chemotaxis -1.52 (↓) 0.009 CCL16(↓);HRG(↓) 140 0.008
Ion transmembrane transport 1.40 (↑) 0.01 CHRNA4(↓);SLCO1B3(↓);CHRNA6(↓);SLCO6A1(↓) 252 0.009
Insulin secretion 1.48 (↑) 0.01 VGF(↓);IRS1(↑);CPLX1(↓) 36 0.04
Cellular response to interleukin-1 -1.63 (↓) 0.01 NKX3-1(↑);RNASE7(↓) 47 0.04
†Similar effects to TRF 6 months male (TRF6M), TRF 6 months female (TRF6F), α-TF 6 months male (TF6M), TRF 6 months male (TRF6M), TRF 6 months 
female(TRF6F), and TRF 3 months male (TRF3M)
Supplementary Table 5 - List of biological processes significantly modulated in male subjects after 3 months of TRF supplementation 
BIOLOGICAL PROCESS/
PATHWAY
GENE SET ENRICHMENT 
ANALYSIS (GSEA)
FISHER’S EXACT TEST: ENRICHED PATHWAYS
Normalized 
enrichment score 
(NES)
p-value Overlapping genes in database Total entities p-value
G-protein coupled receptor 
signaling pathway†TRF3F
1.25 (↑) 0.007
GPR110(↓);PPARD(↑);OR2D2(↓);BAI1(↑);RORB(↓);
GNA14(↑);AVPR1A(↓);LTB4R2(↓)
816 0.009
Response to drug†TF6F,TRF6M,TRF6F -1.26 (↓) 0.007
GATA4(↓);CHRNA3(↓);MMP7(↓);ADAM17(↓);PAM(↓);
ABCA3(↓);LTC4S(↓);CROT(↓);SOCS3(↑);ABAT(↓);
NGF(↓);MET(↑);CKMT2(↓)
450 0.02
Immune system 
process†TF6M,TRF3F,TRF6F
-1.37 (↓) 0.008
CD300LD(↓);IRAK4(↓);IRGM(↑);IL31RA(↓);CADM1(↓);
KLRG1(↓)
265 0.007
Cell division 1.37 (↑) 0.01
MIS12(↓);VPS4B(↓);TACC1(↓);KIF2B(↓);NEDD9(↓);KIF11(↓); 
DSN1(↓); SMC2(↓);AURKA(↓);DCLRE1A(↓);FIGN(↑); 
PARD6A(↑);NUF2(↓);CDC27(↓);TIPIN(↓);TTK(↓)
302 0.03
Aging -1.39 (↓) 0.01 NGF(↓);PHOX2A(↑);CACNA1D(↓) 196 0.005
Regulation of transcription 1.20 (↑) 0.01
CITED4(↑);ZNF221(↓);PAX4(↓);IGSF1(↓);HOXD13(↑);
PPARD(↑);HOXC12(↓);CTNND2(↑)
1092 0.02
†Similar effects to TRF 3 months Female (TRF3F), α-TF 6 months Female (TF6F), TRF 6 months Male (TRF6M), TRF 6 months Female (TRF6F), α-TF 6 months 
Male (TF6M), TRF 3 months Female (TRF3F) 
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Supplementary Table 7 - List of biological processes significantly modulated in female subjects after 3 months of TRF supplementation
BIOLOGICAL PROCESS/
PATHWAY
GENE SET ENRICHMENT 
ANALYSIS (GSEA)
FISHER’S EXACT TEST: ENRICHED PATHWAYS
Normalized 
enrichment score 
(NES)
p-value Overlapping genes in database Total entities p-value
Activation of protein kinase 
activity
1.76 (↑) 0.008 TGFB2(↓);INSR(↓);TOM1L1(↓);EGF(↓) 27 0.04
Response to glucocorticoid 1.33 (↑) 0.009 A2M(↑);MSTN(↓);CCKAR(↓);SCGB1A1(↑);INSR(↓) 131 0.009
Cell surface receptor signaling 
pathway
-1.28 (↓) 0.01 AGT(↑);OSTN(↑);IFNB1(↑);MCHR1(↑);NPPB(↑) 240 0.007
Immune response†TF6M,TRF3M,TRF6F -1.44 (↓) 0.01 IFNB1(↑);KIR2DL2(↑);MADCAM1(↑) 43 0.001
Multicellular organism 
growth†TRF6M,TRF6F
1.20 (↑) 0.01
EFNB2(↓);CDX1(↓);SEMA5A(↓);PPP1R9B(↑);MDFI(↑);
SNAI2(↓);FGF2(↓);HOXA3(↑);NHLH2(↑);NPHS1(↑);
GSX1(↓);BOLL(↑);NEUROD1(↑);FLG(↑);WNT4(↓)
1067 0.003
G-protein coupled receptor 
signaling pathway†TRF6M
1.45 (↑) 0.01
SSTR4(↑);AGT(↑);MCHR1(↑);GPR111(↑);INSR(↓); 
GAST(↓);S1PR4(↑); DRD5(↑); NPBWR2(↑); 
GPR132(↑);CCKAR(↓);
HTR1E(↓);RAPGEF4(↓);FGF2(↓);ADCY1(↑)
824 0.01
†Similar effects to α-TF 6 months male (TF6M), TRF 3 months male (TRF3M), TRF 6 months female (TRF6F), and TRF 6 months male (TRF6M)
Supplementary Table 6 - List of biological processes significantly modulated in male subjects after 6 months of TRF supplementation 
BIOLOGICAL PROCESS/
PATHWAY
GENE SET ENRICHMENT 
ANALYSIS (GSEA)
FISHER’S EXACT TEST: ENRICHED PATHWAYS
Normalized 
enrichment score 
(NES)
p-value Overlapping genes in database Total entities p-value
Multicellular organismal 
development†TRF6F
1.30 (↑) 0.006
BMP3(↓);RORB(↓);CDX1(↑);CTNND2(↑);HOXB7(↓); 
WNT11(↑);NAV1(↑); INSC(↑);HOXC13(↑); 
NGEF(↑);GPSM1(↑);HEG1(↓);KIF26B(↓); 
CSRP3(↑);PKP1(↓);DCLK1(↑)
1067 0.007
Response to drug†TF6F,TRF3M,TRF6F -1.39 (↓) 0.006
CHRNA3(↓);MMP7(↓);ADAM17(↓);KCNJ11(↑);CROT(↓);
CKMT2(↓)
99 0.01
Integrin-mediated signaling 
pathway
-1.44 (↓) 0.007 ADAM7(↓);DOCK1(↓) 263 0.008
Phosphatidylinositol-mediated 
signaling
-1.43 (↓) 0.008 IRAK4(↓);PIK3CG(↓) 133 0.003
Cell-cell signaling -1.40 (↓) 0.008 BMP3(↓);TSHB(↓);CCL4(↓) 263 0.006
Positive regulation of ERK1 
and ERK2 cascade†TRF6F
-1.61 (↓) 0.009 FGF19(↓);GPR183(↑) 101 0.005
Signal transduction†TF6F,TRF6F -1.24 (↓) 0.01
GPR151(↑);PLAU(↑);WNT11(↑);BRS3(↑);PKN3(↓);AVPR1A(↓); 
LTB4R2(↓);LPAR2(↑); HTR1F(↓);RPS6KA2(↓);
KCNIP2(↑);IL21(↑);SPOCK3(↓);BDKRB1(↓);IGSF1(↓);
CTNND2(↑);CABP4(↓);GPR110(↓);FSHB(↑);PKP1(↓)
1156 0.01
Cell adhesion†TF6M,TF6F,TRF6F -1.37 (↓) 0.01 CRNN(↑);PKP1(↓);COL19A1(↓);NCAM2(↓) 99 0.008
†Similar effects to TRF 6 months female (TRF6F), α-TF 6 months female (TF6F), TRF 3 months male (TRF3M), and α-TF 6 months male (TF6M)
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Supplementary Table 8 - List of biological processes significantly modulated in female subjects after 6 months of TRF supplementation 
BIOLOGICAL PROCESS/
PATHWAY
GENE SET ENRICHMENT 
ANALYSIS (GSEA)
FISHER EXACT TEST: ENRICHED PATHWAYS
Normalized 
enrichment score 
(NES)
p-value Overlapping genes in database Total entities p-value
Signal transduction†TF6F,TRF6M -1.20 (↓) 0.006
DGKG(↓);GPR151(↑);PTGDR(↓);CHRNA3(↓);DOCK1(↓);IGFBP4(↑); 
RAP1B(↓);CCL24(↓);NDFIP2(↓);LTB4R2(↓);
HTR1F(↓);SIT1(↑);RPS6KA2(↓);IQGAP2(↓);LGR5(↓);
MRGPRE(↓);EPS8(↓);IGSF1(↓);TRAF4(↑);S1PR4(↑);
STAT5B(↑);TGFBR1(↓);LTA(↑);TLE2(↑);GNG12(↓) 
1236 0.01
+ve regulation of apoptotic 
process
-1.32 (↓) 0.007 RPS6KA2(↓);TFAP4(↑);ANKRD1(↑);EIF5A(↑);DNM1L(↓) 344 0.008
+ve regulation of 
I-kappaB kinase-NF-kappaB 
signaling
-1.61 (↓) 0.008 NDFIP2(↓);S100B(↓);PIM2(↑) 73 0.009
+ve regulation of ERK1 and 
ERK2 cascade†TRF6M
-1.50 (↓) 0.009 FGF19(↓);DOCK1(↓) 101 0.005
Immune response†TF6M,TRF3M,TRF3F -1.50 (↓) 0.01 CCL7(↓);CCL24(↓);YES1(↓);SIRPG(↑);CXCL9(↓);C8B(↓) 113 0.001
Response to drug†TF6F,TRF3M,TRF6M -1.20 (↓) 0.01
LYST(↓);PPARGC1A(↓);MMP7(↓);PCK1(↓);AMH(↓);
HSD3B2(↑);CKMT2(↓)
35 0.01
Cell adhesion†TF6M,TF6F,TRF6M -1.25 (↓) 0.01
COL12A1(↓);NCAM2(↓);GPNMB(↑);BTBD9(↓);
SSX2IP(↓);MMP13(↑)
593 0.001
Multicellular organism 
growth†TRF3F,TRF6M
1.41 (↑) 0.01 KAT2A(↑);HEG1(↓) 76 0.004
G-protein coupled receptor 
signaling pathway
-1.41 (↓) 0.01 KCNJ11(↑);ADCY1(↑);GRIK1(↑); HTR1F(↑);ADCY7(↑) 41 0.01
†Similar effects to α-TF 6 months female (TF6F), TRF 6 months male (TRF6M), α-TF 6 months male (TF6M), TRF 3 months male (TRF3M), and TRF 3 months 
female (TRF3F)
